Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Elevance Health ( (ELV) ) has shared an announcement.
On July 28, 2025, Elevance Health announced the election of Steven H. Collis as an independent director, effective August 1, 2025. Collis, a seasoned healthcare executive, will join the Audit and Finance Committees, enhancing the board’s expertise and governance. His appointment aligns with Elevance Health’s strategy to refresh its board to support growth and stakeholder needs in the evolving healthcare market.
The most recent analyst rating on (ELV) stock is a Buy with a $600.00 price target. To see the full list of analyst forecasts on Elevance Health stock, see the ELV Stock Forecast page.
Spark’s Take on ELV Stock
According to Spark, TipRanks’ AI Analyst, ELV is a Neutral.
Elevance Health’s strong financial performance and valuation are offset by negative technical indicators and challenges highlighted during the earnings call. The company’s robust operational efficiency and solid balance sheet provide a strong foundation, but bearish technical trends and cost pressures in key markets pose significant risks.
To see Spark’s full report on ELV stock, click here.
More about Elevance Health
Elevance Health is a trusted health partner focused on improving the health of humanity. It serves over 109 million consumers with a diverse portfolio of medical, pharmacy, behavioral, clinical, home health, and complex care solutions.
Average Trading Volume: 2,144,574
Technical Sentiment Signal: Sell
Current Market Cap: $65.1B
Find detailed analytics on ELV stock on TipRanks’ Stock Analysis page.